Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

Table 3 Reasons Patients Preferred Fremanezumab by Category of Prior Preventive Treatment^a,b

Prior preventive treatment^c	Antiepileptics N = 130	Antihypertensives N = 62	Tricyclic antidepressants N = 53	OnabotulinumtoxinA N = 28	SSRIs/SNRIs N = 27
Reason for preventive treatment preference, n (%)^d	Preferred fremanezumab n = 119 (91.5%)	Preferred fremanezumab n = 55 (88.7%)	Preferred fremanezumab n = 49 (92.5%)	Preferred fremanezumab n = 23 (82.1%)	Preferred fremanezumab n = 26 (96.3%)
Reduces attack frequency	100 (84.0)	48 (87.3)	40 (81.6)	18 (78.3)	20 (76.9)
Reduces migraine intensity	89 (74.8)	38 (69.1)	38 (77.6)	17 (73.9)	17 (65.4)
Reduces attack duration	81 (68.1)	32 (58.2)	32 (65.3)	14 (60.9)	15 (57.7)
Reduces migraine-associated symptoms	71 (59.7)	27 (49.1)	30 (61.2)	14 (60.9)	15 (57.7)
Reduces migraine-associated disability	74 (62.2)	30 (54.5)	27 (55.1)	14 (60.9)	16 (61.5)
Causes less side effects	78 (65.5)	22 (40.0)	33 (67.3)	8 (34.8)	12 (46.2)
More convenient	45 (37.8)	23 (41.8)	19 (38.8)	8 (34.8)	9 (34.6)
Other	1 (0.8)	0	0	2 (8.7)	2 (7.7)

SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor
^aPatients may have received prior preventive treatments in more than one class, and patients reported their preference for fremanezumab versus the prior treatment for each prior preventive treatment used. Thus, patients in the survey study sample may have reported preference for fremanezumab versus prior treatment for more than one class of treatment
^bPatients responded to the following question for each preventive treatment that they reported having taken in the 5 years prior to the clinical trial: “Overall, which medicine did you prefer more, the injectable medicine you received as part of the clinical trial or (prior migraine preventive medication)?”
^cPreferred prior preventive treatment: antiepileptics, 11 (8.5%); antihypertensives, 7 (11.3%); tricyclic antidepressants, 4 (7.5%); onabotulinumtoxinA, 5 (17.9%); SSRI/SNRI, 1 (3.7%)
^dPercentages were calculated using the number reporting preference for fremanezumab as a denominator

ISSN: 1129-2377